Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalpiciclib - Jiangsu Hengrui Medicine Co.

Drug Profile

Dalpiciclib - Jiangsu Hengrui Medicine Co.

Alternative Names: SHR-6390

Latest Information Update: 20 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Atridia; Jiangsu Hengrui Medicine Co.; Peking University; Shanghai Jiaotong University School of Medicine
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Ketones; Piperidines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Malignant melanoma
  • Phase I Solid tumours
  • Phase 0 Head and neck cancer
  • No development reported Gastric cancer

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for phase-I development in Gastric-cancer(Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (PO)
  • 18 Aug 2021 First Affiliated Hospital of Zhejiang University plans a phase II trial for Breast cancer (Neoadjuvant therapy, Combination therapy, Metastatic disease) in December 2021 (NCT04997798)
  • 06 Aug 2021 Shanghai Hengrui Pharmaceutical plans a phase I trial for Breast cancer (Second-line therapy or greater, Metastatic disease, Combination therapy) in China, in August 2021 (NCT04993430)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top